The effect of tranexamic acid in the treatment of freckles

Evaluating the effectiveness of intradermal tranexamic acid injection in reducing the incidence of post-inflammatory hyperpigmentation and improving the results of facial freckle treatment with a 532 nm Q-switched laser (a randomized, double-blind clinical trial)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250803066735N1

Enrollment

Registered

2025-09-27

Start date

2025-08-23

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Freckle. Freckles

Interventions

Intervention 1: This study is conducted in parallel. Each patient is in both the intervention and control groups. Before the treatment session, the face is cleansed and exfoliated. A topical anestheti

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Having freckles on both sides of the face

Exclusion criteria

Exclusion criteria: People with other pigment diseases such as vitiligo.

Design outcomes

Primary

Measure	Time frame
Freckle size and diameter. Timepoint: Before starting treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Taking pictures with Visiofis.;Freckle density. Timepoint: Before starting treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Taking pictures with Visiofis.	—

Secondary

Measure	Time frame
Patient satisfaction. Timepoint: Before starting treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Questionnaire(SERVQUAL) and interview.;Physician satisfaction. Timepoint: Before starting treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Questionnaire(SERVQAUL).;Biometric results. Timepoint: Before starting treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Photo with visioface and photometer.	—

Measure

Time frame

Patient satisfaction. Timepoint: Before starting treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Questionnaire(SERVQUAL) and interview.;Physician satisfaction. Timepoint: Before starting treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Questionnaire(SERVQAUL).;Biometric results. Timepoint: Before starting treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Photo with visioface and photometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammadreza Ghasemi

Iran University of Medical Sciences

mohammadreza.ghassemi@gmail.com+98 21 8670 2504

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026